Androgenetic alopecia, commonly known as male- or female-pattern hair loss, is the most widespread form of hair loss, yet it remains deeply distressing for those who experience it. While the condition can significantly affect quality of life, physicians point out that early intervention offers real hope for slowing progression or regrowing hair. “You can get on it right away and get patients resources to be successful with it,” said Dr. Renita Ahluwalia, a Toronto dermatologist and co-author of a Canadian consensus guideline on managing the condition, published in the Journal of Cutaneous Medicine and Surgery in 2025.
Alopecia develops through miniaturization of the hair follicle, a shortened growth phase, and a longer resting phase. Women typically notice thinning across the central scalp or diffuse loss, while men often see recession at the temples or crown, according to a 2026 review in CMAJ. In women, the condition can surface alongside telogen effluvium, a shedding phase that sometimes follows childbirth or stopping medications like oral contraceptives. That shedding, Dr. Ahluwalia explained, can unmask an underlying androgenetic alopecia that was previously unnoticed.
Related: Canada’s missed oversight on doctor training may end with AI
When patients first present, physicians watch for red flags such as itching, burning, or pain. Those symptoms can point to scarring alopecia, a more serious condition where follicles are damaged or destroyed. Referrals to dermatologists should note any scalp redness or follicle destruction, as these require urgent assessment.
An initial work-up typically includes checks on ferritin, thyroid function, and vitamin D and B12 levels. Androgen testing is not considered helpful, the CMAJ review states, and a scalp biopsy is generally not needed.
For both men and women, the first-line treatment remains topical 5% minoxidil applied once daily, though a 2% formulation used twice a day is also available. Roughly 10% of patients experience initial shedding, but Dr. Ahluwalia advises continuing treatment through that phase. Men may also take oral finasteride 1 mg daily, though it is not recommended for women of child-bearing age because of potential harm to a fetus. Postmenopausal women can consider it, but only after a discussion about a theoretical increased risk of breast cancer, the consensus guidelines note.
Related: How to Have a Luxurious Diamond Ring While Being Eco-Conscious
For men, the Canadian consensus guidelines list topical finasteride 0.25% daily or oral minoxidil at doses from 1.25 to 5 mg as second-line treatments. Oral dutasteride 0.5 mg two to three times weekly is another option, acting similarly to finasteride but with greater potency. For premenopausal women, oral spironolactone works well, according to Dr. Ahluwalia, and has the added benefit of treating hormonal acne, which often coexists with hair loss. The CMAJ review suggests doses up to 100 mg twice daily, while the guidelines also list oral minoxidil as second-line for these patients.
A 2026 review in the New England Journal of Medicine suggests some women may benefit from a starting oral minoxidil dose of 1.25 mg daily or less to avoid side effects, particularly decreased blood pressure, with gradual titration upward as tolerated.
Patients who can afford cosmetic dermatology procedures may consider low-level laser therapy, which aims to stimulate follicle activity. A 2021 review in the Journal of Cutaneous Aesthetic Surgery found the method safe and potentially effective, and it may work better when combined with pharmaceutical treatment. Platelet-rich plasma (PRP) injections deliver concentrated platelets that release growth factors to encourage follicle regeneration. A 2020 meta-analysis by Canadian dermatologists in Dermatologic Therapy found PRP increases hair diameter in both men and women, though it only increased hair density in men. The NEJM review notes three treatments spaced one month apart are needed to trigger a response.
Related: New AAD guidelines expand eczema treatment options
Microneedling has also shown promise, particularly when paired with minoxidil. Home-use devices like LED helmets and caps have become popular, and some have solid clinical studies behind them, Dr. Ahluwalia said. Hand-held combs delivering low-level light therapy are another option. The guidelines also mention topical ketoconazole, an antifungal that acts as a weak androgen receptor antagonist, along with aminexil, nutraceuticals, and herbal products. These may be more accessible to some patients and can complement other treatments. The physicians involved in the consensus guidelines agreed that patients feel better “when they are doing as much as they can about their hair loss.”
Ongoing research is exploring several treatments, mostly new formulations of existing drugs. These include sublingual and extended-release versions of oral minoxidil, plus a topical finasteride spray. “It’s an area where continuing research is being done because it’s such a common problem and it really affects people’s lives,” Dr. Ahluwalia said. Clinics often use specialized equipment to measure hair loss or regrowth quantitatively. As she put it, “Patients are happy when they feel like they’re growing hair, but we want to actually prove that they are.”
